| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$508.0M | ROE | −45.69% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Denali Therapeutics is a biopharmaceutical company discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases. Its programs include eclitasertib, a RIPK1 inhibitor for peripheral inflammatory diseases; a LRRK2 inhibitor for Parkinson's disease; and enzyme and protein Transport Vehicle programs targeting conditions such as Hunter syndrome, Pompe disease, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease.
| Market Cap | $3.82B | Trading Days | 2163 |
| 52W High | 27.30 |
| 52W Low | 12.58 |
| % Off High | −11.90% |
| YTD | 45.67% | 1Y | 76.45% |
| 3Y | −14.05% | 5Y | −53.32% |
| Since incept. (ann.) | 1.33% |
| Ann. Volatility (1Y) | 58.46% | Ann. Volatility (3Y) | 64.12% |
| Sharpe (1Y) | 1.29 | Sharpe (3Y) | 0.24 |
| Max Drawdown (1Y) | −20.49% | Max Drawdown (3Y) | −63.68% |
| Beta (3Y, vs SPY) | 1.56 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SCNI | Scinai Immunotherapeutics Ltd. | $3.66B | — |
| DBVT | DBV Technologies S.A. | $4.00B | — |
| ADPT | Adaptive Biotechnologies Corp | $3.60B | — |
| RLAY | Relay Therapeutics, Inc. | $3.50B | — |
| CRSP | CRISPR Therapeutics AG | $4.59B | — |
| BEAM | Beam Therapeutics Inc. | $2.70B | — |
| TWST | Twist Bioscience Corp | $5.51B | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.54B | — |
| KOD | Kodiak Sciences Inc. | $2.52B | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.48B | 8.0 |
| SRRK | Scholar Rock Holding Corp |
| $5.92B |
| — |
| VCEL | Vericel Corp | $2.39B | 146.0 |
